MedTrace Logo

Senegal Market Study for Food-to-Food Fortified (F2F) Instant Porridge Flours

NCT05872061 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2023-06-01

No results posted yet for this study

Summary

The overall hypotheses is that a product designed with optimized nutritional characteristics, based on consumer preferences and leveraging local nutrient dense ingredients, can successfully deliver nutrition through sustainable market-driven approaches.

The objectives of this study were 1) to assess the nutritional adequacy of urban Senegalese households with children and 2) to determine the market potential of a locally sourced and manufactured, blended fortified, cereal-based product for the improvement of micronutrient deficiencies among children aged 24-60 months. This study simulates a market study, the investigators will conduct a product launch, determine market potential based on sales, evaluate marketing strategy to increase market share, and model the nutritional contribution of FtFF/traditionally fortified product for iron, zinc, and vitamin A. The investigators expect to provide a thorough evaluation of a business-driven strategy (for profit, social enterprise) as a sustainable tool to decrease micronutrient deficiencies.

Conditions

  • Iron-deficiency
  • Vitamin A Deficiency

Interventions

OTHER

Acceptability of food-to-food fortified (FtFF) instant porridge flours

This study will evaluate the market potential of a food-to-food fortified (FtFF) flour.

Sponsors & Collaborators

  • Purdue University

    lead OTHER

Principal Investigators

  • Bruce R Hamaker, PhD · Purdue University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-27
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Senegal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05872061 on ClinicalTrials.gov